Simultaneous pancreas and kidney transplant after bilateral lung transplant for a recipient with Cystic Fibrosis

2021 ◽  
Author(s):  
Jonathan A. Fridell ◽  
Andrew J. Lutz ◽  
John A. Powelson
Keyword(s):  
Cystic Fibrosis ◽  
Kidney Transplant ◽  
Lung Transplant ◽  
Bilateral Lung

Marathon with cystic fibrosis and bilateral lung transplant

2000 ◽  
Vol 10 (1) ◽  
pp. 42-46 ◽  
Author(s):  
J. K. Stanghelle ◽  
J. O. Koss ◽  
O. Bjortuft ◽  
O. Geiran
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplant ◽  
Bilateral Lung

National Healthcare Delivery Systems Influence Lung Transplant Outcomes for Cystic Fibrosis

2015 ◽  
Vol 15 (7) ◽  
pp. 1948-1957 ◽  
Author(s):  
C. A. Merlo ◽  
S. C. Clark ◽  
G. J. Arnaoutakis ◽  
N. Yonan ◽  
D. Thomas ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplant ◽  
Healthcare Delivery ◽  
Delivery Systems ◽  
Transplant Outcomes ◽  
National Healthcare ◽  
Healthcare Delivery Systems

Impact of cystic fibrosis-related diabetes (CFRD) on lung transplant outcomes

2004 ◽  
Vol 23 (2) ◽  
pp. S93 ◽  
Author(s):  
M.R Zamora ◽  
L.B Edwards ◽  
D Weill ◽  
T.L Astor ◽  
M.R Nicolls
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplant ◽  
Transplant Outcomes

Tacrolimus-Induced Bradykinesia Secondary to Phenoconversion in an Elderly Post-Bilateral Lung Transplant Patient

2021 ◽  
Vol 36 (1) ◽  
pp. 34-41
Author(s):  
Lia Argevani ◽  
Michael J. Schuh ◽  
Sheena Crosby
Keyword(s):  
Adverse Effects ◽  
Drug Combination ◽  
Lung Transplant ◽  
Transplant Patient ◽  
Mortality And Morbidity ◽  
Risk Of Falls ◽  
Bilateral Lung ◽  
Morbidity Risk

Objective: To report pharmacogenomics post-related bradykinesia secondary to phenoconversion in an elderly post-bilateral lung transplant patient. Summary: The patient was a 68-year-old double lung transplant patient taking the immunosuppressant and CYP3A4/5 substrate tacrolimus concomitantly with 2 CYP3A4/5 inhibitor medications, fluconazole and diltiazem. This drug combination post-dosing resulted in debilitating bradykinesia 1-2 hours after dosing, increasing the risk of falls and possible increased mortality and morbidity risk. Conclusion: Taking tacrolimus in combination with CYP3A4/5 inhibitors may increase neurologic adverse effects resulting in increased fall and associated increased mortality and morbidity risk.

scholarly journals Lung Transplant for Cystic Fibrosis

2013 ◽  
Vol 2 (3) ◽  
pp. 180-186 ◽  
Author(s):  
David Weill ◽  
Kapil Patel
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplant
Sign in / Sign up

Export Citation Format

Share Document